Company news
Novartis Ag (SIX:NOVN) news
Every Novartis Ag press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Novartis receives Health Canada approval for (Pr)RHAPSIDO® (remibrutinib tablets) oral treatment for adults with CSU
July 27, 2026
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney func...
July 16, 2026
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
July 6, 2026
Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics
July 6, 2026
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding ...
July 6, 2026
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
July 2, 2026
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
June 12, 2026
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker end...
June 11, 2026
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
June 8, 2026
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
June 4, 2026
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
June 3, 2026
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
June 1, 2026
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
June 1, 2026
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
May 31, 2026
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
May 26, 2026
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
May 21, 2026
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
May 17, 2026
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
May 7, 2026
Model N Appoints Thomas Gibbs to Board of Directors
May 5, 2026
Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G
May 1, 2026
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
April 30, 2026
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
April 28, 2026
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
April 27, 2026
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
April 24, 2026
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
April 24, 2026
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countrie...
April 9, 2026
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
March 29, 2026
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response ...
March 27, 2026
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
March 27, 2026
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
March 23, 2026
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
March 20, 2026
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
March 13, 2026
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
March 6, 2026
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA str...
February 27, 2026
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
February 27, 2026
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
February 25, 2026
Novartis AG Enterprise Technology Report 2025: Digital Transformation Strategies, Innovation Programs, Technology Initiatives, Partnershi...
February 25, 2026
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
February 24, 2026
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
February 23, 2026
Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutath...
February 19, 2026
Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics
February 18, 2026
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
February 18, 2026
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | Delv...
February 17, 2026
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
February 13, 2026
Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies
February 11, 2026
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
February 6, 2026
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
February 4, 2026
NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"
January 29, 2026
Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Pr...
January 27, 2026
Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)
January 25, 2026